Should You Buy, Hold, or Sell UnitedHealth Group (UNH) Stock After Its Recent Rally?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 19 2025
0mins
Source: NASDAQ.COM
Stock Performance: UnitedHealth Group's stock (UNH) is down 40% year-to-date but has increased over 20% this month due to investments from Warren Buffett's Berkshire Hathaway and other hedge fund managers.
Value Investing Insight: Buffett's investment in UNH reflects a classic value investing strategy, seeing potential long-term value despite the company's current challenges, including a DOJ investigation and high medical costs.
Earnings Projections: The company has revised its fiscal 2025 EPS guidance downward significantly, with FY26 EPS estimates also dropping nearly 30%, raising concerns among investors about future profitability.
Investment Alternatives: Analysts suggest that for those wary of UNH's volatility, investing in the iShares U.S. Healthcare Providers ETF (IHF) may provide a safer exposure to the healthcare sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNH
Wall Street analysts forecast UNH stock price to rise
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 316.400
Low
330.00
Averages
397.82
High
444.00
Current: 316.400
Low
330.00
Averages
397.82
High
444.00
About UNH
UnitedHealth Group Incorporated is a healthcare and well-being company. Its segments include Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State. Optum Health provides comprehensive and patient-centered care, addressing the physical, mental, and social well-being. Optum Health delivers primary, specialty and surgical care and helps patients and providers navigate and address complex, chronic and behavioral health needs. Optum Insight connects the healthcare system with services, analytics and platforms that make clinical, administrative and financial processes simpler and more efficient for all participants in the healthcare system. Optum Rx offers a range of pharmacy care services through retail pharmacies, through home delivery, specialty and community health pharmacies and the provision of in-home and community-based infusion services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Ratings and Outlook from Wall Street
- Apple Maintained as Buy: Bank of America reiterated its buy rating on Apple (AAPL), labeling it as the “highest quality name,” and despite underperformance year-to-date, it is still viewed as a high-quality compounder supported by resilient services growth and a healthy product cycle.
- Semiconductor Sector Pressure: Mizuho downgraded NXP Semiconductors (NXPI) to sell, citing its significant exposure to the auto sector as a headwind, with the 2026 auto outlook softened by geopolitical and macroeconomic challenges.
- Netflix's Solid Performance: Bank of America reaffirmed its buy rating on Netflix following a solid first quarter that modestly beat forecasts, with management reiterating three core priorities that align with their ongoing strategic focus and competitive positioning in the market.
- Petrobras Rating Upgrade: Bank of America upgraded Petrobras (PBR) from neutral to buy, highlighting its robust cash flow generation and low double-digit dividend yield, which reduces the risk of a potential revision to its dividend policy in a high oil price environment.
See More
Nasdaq Matches 12-Day Winning Streak, Highest Since 2009
- Nasdaq Performance: The Nasdaq index has surged 15% over the past 12 trading days, marking the longest winning streak since 2009, indicating a strong market recovery and renewed investor confidence.
- Major Index Rebounds: During the same period, the Dow Jones Industrial Average rose 7.5% and the S&P 500 increased by 12.5%, with both tech and communication services sectors up 13%, reflecting a preference for technology stocks in the market.
- Regional Bank Dynamics: Fifth Third Bancorp has risen 0.7% over the last three months but remains 11% below its 52-week high; Regions Financial is up 0.5%, also 11% below its 52-week peak, highlighting pressures faced by regional banks.
- Netflix Earnings Reaction: Despite Netflix exceeding expectations in its quarterly report and seeing a 15% year-to-date increase, its stock fell 9% in after-hours trading due to investor dissatisfaction with future guidance, reflecting caution regarding future growth.
See More
Three Biotech Companies Worth Watching
- Krystal Biotech's Breakthrough: In 2023, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue, a 34% year-over-year increase, indicating strong market potential in rare diseases.
- Madrigal Pharmaceuticals' FDA Approval: In 2024, Madrigal gained FDA approval for Rezdiffra, the first drug for metabolic dysfunction-associated steatohepatitis, with 2025 revenue reaching $958.4 million, a staggering 432% increase, showcasing robust growth in an emerging market.
- Exelixis' Oncology Innovations: Exelixis' Cabometyx remains the leading treatment for liver and kidney cancers, with no generic competition expected until 2030, while the company plans to launch several next-gen cancer therapies in the next five years, further solidifying its market position.
- Significant Market Potential: The combination of innovation and market demand in these three companies suggests that their stocks could yield substantial returns in the future, particularly in the ongoing developments within rare diseases and oncology.
See More
Jessica Tisch's Leadership Approach as NYPD Commissioner
- Leadership Style: Just two weeks into her tenure as NYPD Commissioner, Jessica Tisch faced the high-profile shooting of UnitedHealthcare CEO Brian Thompson, showcasing her collaborative leadership style by relying on experienced police chiefs, which maintained decision-making transparency and effectiveness during the crisis.
- Technological Modernization: Tisch discovered in 2010 that the NYPD's technology infrastructure was severely lacking, with many officers lacking cell phones or email, and she has since driven modernization efforts while ensuring that the introduction of new technologies does not compromise public trust, emphasizing the priority of privacy policies.
- Talent Development: She believes that the key to success lies in identifying and cultivating talent, and despite being a relatively young leader managing seasoned police personnel, she has earned their trust through preparation and transparency, demonstrating her extensive experience across various agencies.
- Significant Results: Under Tisch's leadership, the NYPD has achieved notable reductions in key areas such as subway crime, shootings, and retail theft, with retail theft down 14% in 2022 and over 20% so far in 2026, indicating the positive impact of her policies on public safety.
See More
Three Biotech Stocks Worth Watching
- Krystal Biotech's Breakthrough: Focused on rare diseases, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue in 2023, a 34% year-over-year increase, indicating strong market performance.
- Madrigal Pharmaceuticals' Market Potential: Madrigal's Rezdiffra, approved by the FDA in 2024 as the first treatment for metabolic dysfunction-associated steatohepatitis, generated $958.4 million in revenue in 2025, a staggering 432% increase, showcasing its potential in a large patient market.
- Exelixis' Innovative Drugs: Exelixis' Cabometyx, a leading treatment for liver and kidney cancers, is expected to face no generic competition until 2030, while its development of next-gen cancer therapies could further drive growth in the coming years.
- Competitive Advantages: These three companies demonstrate significant market potential and innovation capabilities, with Krystal Biotech and Madrigal expanding their product lines to enhance market share, while Exelixis maintains a strong position in oncology through robust financial performance and R&D efforts.
See More
Medicare Payment Increase Boosts CVS Stock Recovery
- Impact of Medicare Policy: The CMS's finalized Medicare payment increase of nearly 2.5% significantly improves the profitability outlook for CVS and other healthcare stocks, leading to a stock price rebound compared to the previously proposed 0.09% increase.
- Upgraded Earnings Expectations: Analysts project CVS's earnings per share to reach between $7 and $7.20 in 2026, with the increase in Medicare payments likely enhancing CVS's profitability and boosting market confidence.
- Stock Valuation Potential: Currently trading at around 11 times forward earnings, CVS could see its stock price rise to $90 or $100 if it narrows the valuation gap with competitors like UnitedHealth Group, offering substantial investment returns.
- Stable Dividend Yield: With a forward dividend yield of 3.4%, CVS not only provides steady income but also attracts long-term investors, further supporting the upward momentum of its stock price.
See More
Latest Ratings and Outlook from Wall Street
- Apple Maintained as Buy: Bank of America reiterated its buy rating on Apple (AAPL), labeling it as the “highest quality name,” and despite underperformance year-to-date, it is still viewed as a high-quality compounder supported by resilient services growth and a healthy product cycle.
- Semiconductor Sector Pressure: Mizuho downgraded NXP Semiconductors (NXPI) to sell, citing its significant exposure to the auto sector as a headwind, with the 2026 auto outlook softened by geopolitical and macroeconomic challenges.
- Netflix's Solid Performance: Bank of America reaffirmed its buy rating on Netflix following a solid first quarter that modestly beat forecasts, with management reiterating three core priorities that align with their ongoing strategic focus and competitive positioning in the market.
- Petrobras Rating Upgrade: Bank of America upgraded Petrobras (PBR) from neutral to buy, highlighting its robust cash flow generation and low double-digit dividend yield, which reduces the risk of a potential revision to its dividend policy in a high oil price environment.
See More
Nasdaq Matches 12-Day Winning Streak, Highest Since 2009
- Nasdaq Performance: The Nasdaq index has surged 15% over the past 12 trading days, marking the longest winning streak since 2009, indicating a strong market recovery and renewed investor confidence.
- Major Index Rebounds: During the same period, the Dow Jones Industrial Average rose 7.5% and the S&P 500 increased by 12.5%, with both tech and communication services sectors up 13%, reflecting a preference for technology stocks in the market.
- Regional Bank Dynamics: Fifth Third Bancorp has risen 0.7% over the last three months but remains 11% below its 52-week high; Regions Financial is up 0.5%, also 11% below its 52-week peak, highlighting pressures faced by regional banks.
- Netflix Earnings Reaction: Despite Netflix exceeding expectations in its quarterly report and seeing a 15% year-to-date increase, its stock fell 9% in after-hours trading due to investor dissatisfaction with future guidance, reflecting caution regarding future growth.
See More
Three Biotech Companies Worth Watching
- Krystal Biotech's Breakthrough: In 2023, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue, a 34% year-over-year increase, indicating strong market potential in rare diseases.
- Madrigal Pharmaceuticals' FDA Approval: In 2024, Madrigal gained FDA approval for Rezdiffra, the first drug for metabolic dysfunction-associated steatohepatitis, with 2025 revenue reaching $958.4 million, a staggering 432% increase, showcasing robust growth in an emerging market.
- Exelixis' Oncology Innovations: Exelixis' Cabometyx remains the leading treatment for liver and kidney cancers, with no generic competition expected until 2030, while the company plans to launch several next-gen cancer therapies in the next five years, further solidifying its market position.
- Significant Market Potential: The combination of innovation and market demand in these three companies suggests that their stocks could yield substantial returns in the future, particularly in the ongoing developments within rare diseases and oncology.
See More
Jessica Tisch's Leadership Approach as NYPD Commissioner
- Leadership Style: Just two weeks into her tenure as NYPD Commissioner, Jessica Tisch faced the high-profile shooting of UnitedHealthcare CEO Brian Thompson, showcasing her collaborative leadership style by relying on experienced police chiefs, which maintained decision-making transparency and effectiveness during the crisis.
- Technological Modernization: Tisch discovered in 2010 that the NYPD's technology infrastructure was severely lacking, with many officers lacking cell phones or email, and she has since driven modernization efforts while ensuring that the introduction of new technologies does not compromise public trust, emphasizing the priority of privacy policies.
- Talent Development: She believes that the key to success lies in identifying and cultivating talent, and despite being a relatively young leader managing seasoned police personnel, she has earned their trust through preparation and transparency, demonstrating her extensive experience across various agencies.
- Significant Results: Under Tisch's leadership, the NYPD has achieved notable reductions in key areas such as subway crime, shootings, and retail theft, with retail theft down 14% in 2022 and over 20% so far in 2026, indicating the positive impact of her policies on public safety.
See More
Three Biotech Stocks Worth Watching
- Krystal Biotech's Breakthrough: Focused on rare diseases, Krystal Biotech received approval for Vyjuvek, a gene therapy for Dystrophic Epidermolysis Bullosa, achieving $389.1 million in revenue in 2023, a 34% year-over-year increase, indicating strong market performance.
- Madrigal Pharmaceuticals' Market Potential: Madrigal's Rezdiffra, approved by the FDA in 2024 as the first treatment for metabolic dysfunction-associated steatohepatitis, generated $958.4 million in revenue in 2025, a staggering 432% increase, showcasing its potential in a large patient market.
- Exelixis' Innovative Drugs: Exelixis' Cabometyx, a leading treatment for liver and kidney cancers, is expected to face no generic competition until 2030, while its development of next-gen cancer therapies could further drive growth in the coming years.
- Competitive Advantages: These three companies demonstrate significant market potential and innovation capabilities, with Krystal Biotech and Madrigal expanding their product lines to enhance market share, while Exelixis maintains a strong position in oncology through robust financial performance and R&D efforts.
See More
Medicare Payment Increase Boosts CVS Stock Recovery
- Impact of Medicare Policy: The CMS's finalized Medicare payment increase of nearly 2.5% significantly improves the profitability outlook for CVS and other healthcare stocks, leading to a stock price rebound compared to the previously proposed 0.09% increase.
- Upgraded Earnings Expectations: Analysts project CVS's earnings per share to reach between $7 and $7.20 in 2026, with the increase in Medicare payments likely enhancing CVS's profitability and boosting market confidence.
- Stock Valuation Potential: Currently trading at around 11 times forward earnings, CVS could see its stock price rise to $90 or $100 if it narrows the valuation gap with competitors like UnitedHealth Group, offering substantial investment returns.
- Stable Dividend Yield: With a forward dividend yield of 3.4%, CVS not only provides steady income but also attracts long-term investors, further supporting the upward momentum of its stock price.
See More
